To celebrate Black History Month, we take a look back at some of the great Black scientists and innovators. From laser eye surgery to the gas mask, here are some of the seminal contributions made by these ingenious inventors.

[1] Lewis Howard Latimer – Image credit: Unknown author Unknown author, Public domain, via Wikimedia Commons
[2] Leonidas Berry - Image credit: Adundi, CC BY-SA 4.0, https://creativecommons.org/licenses/by-sa/4.0, via Wikimedia Commons
[3] Betty Harris – Image credit: https://www.blackpast.org/african-american-history/harris-betty-wright-1940/ - Fair use image
[4] Patricia Bath - Image credit: National Library of Medicine, Public domain, via Wikimedia Commons
[5] Philip Emeagwali - Image credit: SakaMese, CC BY-SA 4.0, https://creativecommons.org/licenses/by-sa/4.0, via Wikimedia Commons

1880 – Johnson Powell
Have you ever used eye protectors to protect yourself against the glare of intense light? For those working in extreme environments such as fires and furnaces, Johnson Powell’s eye protectors will have been a sight for sore eyes.

1881 – James Wormley
James Wormley invented a life-saving apparatus for boats. His contraption included a string of floats that extended from a ship’s side via a sliding rod with projecting arms. The famous hotelier was also said to be at President Abraham Lincoln’s bedside when he died.

Image Credit: Unknown author, Public domain, via Wikimedia Commons

1882 – Lewis Howard Latimer
Lewis Howard Latimer is probably best known for inventing a durable carbon filament that was key to the success of the electric light bulb. Latimer also invented an evaporative air conditioner and even drafted the drawings to secure the patent for Alexander Graham Bell’s little known invention… the telephone.

>> Click here for more on Lewis Howard Latimer’s extraordinary contribution to science.

1912 – Garrett Morgan
Imagine using your own invention to save people’s lives? That’s exactly what Garrett Morgan did when he donned his patented smoke hood to rescue trapped men from a smoke-filled tunnel beneath Lake Erie. Morgan’s device later evolved into a gas mask, and he also invented a three-position traffic signal, hair straightening cream, and a self-extinguishing cigarette for good measure.

1916 – Madeline M. Turner
Madeline M. Turner’s ingenious invention was the fruit of her own frustration. Turner grew tired of squeezing oranges for her glass of juice, so she created the fruit press machine to solve the problem.

1932 – Richard Spikes
It’s safe to say Richard Spikes was a polymath. The American inventor created an automatic gear shift device for cars, a pressurised beer tap, and a horizontally swinging barber’s chair – all while working as a teacher and barber and being a capable pianist and violinist.

Image Credit: Adundi, CC BY-SA 4.0, via Wikimedia Commons

1966 – Leonidas Berry
This doctor and civil rights advocate invented the Eder-Berry gastroscopy endoscope in 1955, which helped doctors to biopsy the inside of the stomach without surgery. According to the US National Library of Medicine, ‘the Eder-Berry biopsy attachment made the gastroscope the first direct-vision suction instrument used for taking tissue samples during gastroscopic examination’.

Image Credit: https://www.blackpast.org/african-american-history/harris-betty-wright-1940/ - fair use image

1984 – Betty Harris
Perhaps the most explosive discovery of all belongs to Betty Harris. Harris’ spot test for detecting 1,3,5-triamino-2,4,6-trinitrobenzene in the field is used by US Homeland Security today to check for nitroaromatic explosives. In her spare time, Harris has even found the time to work with the Girl Scouts to develop a badge based on Chemistry.

>> SCI is proud to support #BlackinChem. Take a look at some of our recent work.

Image Credit: National Library of Medicine, Public domain, via Wikimedia Commons

1988 – Patricia Bath
Patricia Bath has helped return the gift of sight to thousands of people. The US ophthalmologist invented a quick and painless device that dissolves cataracts with a laser and cleans the eye, enabling the simple insertion of a new lens. Her laserphaco probe is still in use today.

Image Credit: Philip Emeagwali - SakaMese, CC BY-SA 4.0, via Wikimedia Commons

1989 – Philip Emeagwali
Nigerian computer scientist Philip Emeagwali won the prestigious1989 Gordon Bell Prize in Price Performance for a high-performance computer application that used computational fluid dynamics in oil-reservoir modelling. In the same year, Emeagwali also claimed to perform the world’s fastest computation – 3.1 billion calculations per second – using just the power of the internet.

2002 – Donald K. Jones
Donald K Jones made a notable contribution to medicine with his invention of a detachable balloon embolisation device that reduces the size of aneurysms (bulges in blood vessels). The endovascular occlusion device is implanted into the body, whereupon its clever balloon system and adhesive materials reduce the size of aneurysms.

>> Which barriers still block the way for Black chemists? Read Claudio Lourenco’s story.

We need to create more diverse paths into research and scientific innovation. Professor Dame Ottoline Leyser, Chief Executive of UK Research and Innovation, explains how industry clusters and a change of mindset could help.

What do you picture when someone mentions a chemist? Maybe you see someone like you working in a lab or office with your colleagues.

But what do people at the bus stop think? What would a secondary school student say? Do they see someone like them – or do they imagine an Einstein-like figure hidden away in a dark room with crazed hair and test tubes?

One of the most interesting messages from Professor Dame Ottoline Leyser’s Fuelling the Future: science, society and the research and innovation system talk on 29 September was the need to make sure science and technology are seen as viable careers for people throughout society.

Prof Dame Ottoline Leyser

You don’t need to be a genius to work in research and innovation. You don’t necessarily need to be a specialist, and you certainly don’t need to be hunched over a microscope with a jumble of figures and formulae on a board behind you. An array of different people, technical and non-technical, are needed to make the sector thrive.

The narrow pathway of talent

Part of Dame Ottoline’s job as Chief Executive of UK Research and Innovation (UKRI) is to improve access to these sectors and to make sure that great ideas aren’t lost due to daunting entry barriers.

‘It’s a huge challenge,’ she said. ‘A large part of the challenge is the narrow concept that we all have of what a researcher and innovator look like.’

Leyser spoke about the need to create diverse routes through the system rather than squeezing everyone through the same narrow path. ‘The assessment criteria we use for individuals have become narrower and narrower,’ she added. ‘Some of it, ironically, is to make the system fairer, but objectivity in creativity is a total pipe dream. You end up crushing creativity by narrowing the criteria.’

She noted that those with mixed careers – interwoven with varied experiences – are to be welcomed. ‘That’s nothing to do with compromising excellence,’ she said. ‘Real excellence comes in multiple forms.’

>> Would you like to attend more talks like this one? Check out our Events page.

Challenging times

However, Leyser also spoke of the need to level up the UK from a productivity perspective. One way to do this is through smart specialisation and industry clusters. She mentioned Lincoln as an area where this approach worked well. Lincoln is home to extensive agriculture and the multinational technology corporation Siemens. As such, it made sense to help make it a centre for agricultural robotics.

UKRI is investing heavily in research and innovation into Net Zero energy solutions.

As the largest public funder of research and innovation in the UK, UKRI has a major role to play in funding such industry clusters and intelligent innovation. It has funded more than 54,000 researchers and innovators, and UKRI grants have generated almost 900 spinouts since 2004.

These include Oxford Nanopore, a biotech company whose DNA sequencing technology is now valued at £2.5bn. It has also cast an eye on the future, including delivering more than £1bn in R&D relevant to Artificial Intelligence and in excess of £1bn towards Net Zero energy solutions.

Leyser noted that the UKRI’s goal is to embed research and innovation more broadly across society – for it to be ‘by the people and for the people, rather than the exclusive domain of the privileged few’.

It is a grand challenge, but such sentiments are certainly encouraging.

Continuing our series on Black scientists, Dr George Okafo tells us about his journey from curious child, encouraged by family and mentors, to Global Director of Healthcare Data and Analytics with a leading pharmaceutical company.

What is your current position?
I am Global Director, Healthcare Data and Analytics Unit at Boehringer Ingelheim, and have been in this role for the past 10 months.

Right: Dr George Okafo

Please give us a brief outline of your role.
To build an expert team of data stewards, data scientists and statistical geneticists tasked with accessing and ingesting population-scale healthcare biobanks and then deriving target, biomarker and disease insights from this data to transform clinical development and personalise the development of new medicines.

What was it that led you to study chemistry/science and ultimately develop a career in this field? Was this your first choice?
My interest in science stems from my parents. My father was a medical doctor, and my mother was a senior midwife. As a child, I was always very curious and wanted to know why and how things worked. This curiosity has stayed with me all my life and throughout my career at GlaxoSmithKline and now at Boehringer Ingelheim. In my current role, I am still asking the same types of questions from Big Data and these answers could have a profound impact in the development of new medicines.

Was there any one person or group of people who you felt had a specific impact on your decision to pursue the career you are in?
Yes, my father and mother, who supported, encouraged and gave me the confidence to be curious, to keep trying and to never give up.

Dr Okafo held senior director-level roles in drug discovery and development while at at GSK.

Could you outline the route that you took to get to where you are now, and how you were supported?
My career journey started at Dulwich College (London) where I studied Chemistry, Biology, Maths and Physics at A Level. This took me to Imperial College of Science, Technology and Medicine (London), where I completed my Joint BSc in Chemistry and Biochemistry and my PhD in Cancer Chemistry.

I then spent a year at the University of Toronto in Canada as a Postdoctoral Fellow, before embarking on my career in the Pharmaceutical Industry, starting at GlaxoSmithKline (GSK). I spent 30 years at GSK, where I held many senior director-level roles in drug discovery and development. During my time, I made it my mission to learn as much about the R&D process and used this knowledge to understand how innovation can impact and transform drug research.

I have been very fortunate in my career to be surrounded by many brilliant and inspirational people who had the patience to share their knowledge with me and answer my many questions.

>> Curious to read more about some of the great Black scientists from the past? Here’s our blog on Lewis Howard Latimer.

Considering your own career route, what message do you have for Black people who would like to follow in your footsteps?
Surround yourself with brilliant people who can inspire you. Look for people who you respect and can coach and mentor you. Don’t be afraid to fail. Work hard and keep trying.

What do you think are the specific barriers that might be preventing young Black people from pursuing chemistry/science?
No, I do not see colour as a barrier nor a hindrance to pursuing a career in science. I think it is important to look for role models from the same background to help inspire you, to answer your questions and to encourage you.

What steps do you think can be taken by academia and businesses to increase the number of Black people studying and pursuing chemistry/science as a career?
Have more role models from different backgrounds. This sends a very powerful message to young people studying science reinforcing the message… I can do that!

Could you share one experience which has helped to define your career path?
Not so much an experience, but a mindset – staying curious, inquisitive, always willing to learn something new, having courage that failure is not the end, but an opportunity to learn.

Marking Black History Month and following on from the #BlackInChem initiative, SCI is continuing its look back at some of the unsung Black scientists who pioneered, and made important contributions, to the advancement of science.

Today we profile Lewis Howard Latimer, much admired by his contemporaries; Alexander Graham Bell and Thomas Edison, but sadly a name, and story, that is not as well known.

Lewis Howard Latimer | Image Credit: By Unknown author - http://www.lrc.rpi.edu/resources/news/pressReleases/img/Lewis.jpg, Public Domain, https://commons.wikimedia.org/w/index.php?curid=2032528

Lewis Howard Latimer, the youngest of four children, was born in Chelsea, Massachusetts, on 4 September 1848. His father, George Latimer, a slave who had escaped, became something of a cause celebre when his owner recaptured him. However, abolitionists took his case to the Supreme Court and his freedom was secured.

Lewis proved to be an excellent student, with a particular flair for drawing, as well as writing poetry and stories, but lack of finance and restricted access to education meant that by 15 years of age, Lewis had joined the US Navy. The history books indicate that he was honourably discharged in 1865; when the Civil War ended.

Soon after, Latimer found work as an office boy with the patent firm Crosby, Halstead and Gould. It is here that combining his talent for drawing, and developing the skills of a draughtsman he was eventually promoted to the position of head draftsman. The history books record that Latimer’s first patent, in 1874 with colleague Charles Brown, was an improved toilet system for railroad cars.

Lewis Latimer was instrumental in helping Alexander Graham Bell file his patent for the telephone ahead of his competitors.

Latimer had many inventions, but it could be argued that his drawings for Alexander Graham Bell’s telephone, helped seal his place in science history. The story goes that Bell was in a race against time, as rivals were also looking to gain patent rights for a similar device. Bell hired Latimer who used his expertise in drawing and submitting patent applications to help Bell file his patent just hours, it said, before his rival in 1876.

By 1880 Latimer had taken up the post of mechanical draughtsman for the inventor Hiram Maxim, who was also the founder of the US Electric Lighting Company. Now focused on incandescent lighting, Latimer along with Joseph Nichols, invented a light bulb which used a carbon filament, an improvement on Thomas Edison’s paper filament. The invention, patented in 1881, was sold to the US Electric Lighting Company in the same year.

Latimer invented a process for making carbon filaments for light bulbs | Editorial credit: Claudio Zaccherini / Shutterstock.com

¹A booklet by the Thomas Alva Edison Foundation noted; ‘Latimer invented and patented a process for making carbon filaments for light bulbs. He taught the process to company workers, and soon it was being used in factory production. Latimer also assisted in installing Maxim lighting systems in New York City, Philadelphia, Montreal and London. During the installation of lighting in Montreal, where a lot of people spoke only French, Latimer learned the language in order to competently instruct the workers. In London he set up the first factory for the Maxim-Weston Electric Light Company. That required him to teach the workmen all the processes for making Maxim lamps, including glass blowing. In just nine months Latimer had the factory in full production.’

In 1882 Latimer left Hiram Maxim and in 1884 joined the Edison Electric Light Company, where he was given the title draughtsman-engineer. In 1890 he joined the Edison Legal Department, and in 1893 testified in a case where the company said that its incandescent lamp patents had been infringed. In 1896 the Board of Patent Control of GE and Westinghouse was formed and Latimer became its Chief Draughtsman. He continued in that role until 1911 when he joined the consulting firm Edwin W Hammer.

On 24 January 1918, Latimer was named one of the 28 charter members – and the only African-American member – of the Edison Pioneers, ‘a distinguished group of people who worked to keep the ideals of Thomas Edison alive.’ The Edison Pioneers helped create the US’ electric power industry.

Latimer received patents for several inventions, including the safety elevator. He also had a passion for social justice. In a letter written in 1895 in support of the National Conference of Coloured Men, Latimer wrote: ‘I have faith to believe that the nation will respond to our plea for equality before the law, security under the law, and an opportunity, by and through maintenance of the law, to enjoy with our fellow citizens of all races and complexions the blessings guaranteed us under the constitution.’

Latimer died on 11 December 1928. Edison Pioneers historian and long time private secretary of Thomas Edison, William H. Meadowcroft wrote1 ‘Lewis Howard Latimer was of the coloured race, the only one in our organisation, and was one of those to respond to the initial call that led to the formation of the Edison Pioneers, January 24 1918. Broadmindedness, versatility in the accomplishment of things intellectual and cultural, a linguist, a devoted husband and father, all were characteristics of him, and his genial presence will be missed from our gatherings…We hardly mourn his inevitable going so much as we rejoice in pleasant memory at having being associated with him in a great work for all peoples under a great man.’

¹For more information on Latimer’s life, work and legacy, see the Edison Electric Institute resource: Thomas Alva Edison Associate: Lewis Howard Latimer: A Black Inventor.

SCI’s America International group has awarded the 2021 Perkin Medal to Dr Jane Frommer. The 114^th Perkin Medal was presented to Jane at the Bellevue Hotel in Philadelphia, Pennsylvania, in recognition of her outstanding contribution to chemistry.

Dr Jane Frommer

Dr Frommer is renowned for her key contributions in electronically conducting polymers and scanning probe instrumentation. Her pioneering work with scanning probes paved the way for their use in chemistry, materials science and, eventually, in nanotechnology. According to SCI America, her nanoscopic analytic methods are vital to nanostructural research and are used across many industries.

Dr Frommer began her career in 1980 at Allied Corporate Laboratories (now Honeywell), where she created the solution state of electronically conducting organic polymers. In 1986, she joined IBM where, along with other instrumentalists, she demonstrated the ability to image and manipulate single molecules using scanning tunnelling microscopy. During her multi-year assignment at the University of Basel Physics Institute in the early 1990s, Dr Frommer’s team expanded the capability of scanning probes in measuring the functional properties of organic thin films with atomic force microscopy.

Since 2018, she has worked as a science advisor for Google. In this capacity, she has sought to increase the amount of open source data available in the physical and life sciences. She also helps Silicon Valley start-ups navigate the chemical and material challenges of nanotechnology and has mentored countless students and young scientists in high school, college, and in her laboratory in recent decades.

Previous recipients of the Perkin medal include Barbara Haviland Minor, of the Chemours Company, and Ann E Weber, of Kallyope Inc.

Dr Frommer has written more than 100 referred publications and is the co-inventor of more than 50 issued patents. With her extraordinary body of work spanning more than 40 years, she is a worthy recipient of the prestigious Perkin Medal.

The Perkin Medal is widely acknowledged as the highest honour in American industrial chemistry. It was established to commemorate the 50^th anniversary of William Henry Perkin’s discovery of mauveine at the age of just 18. Perkin’s creation of mauveine, the world’s first synthetic aniline dye, revolutionised chemistry and opened up new frontiers in textiles, clothing, and other industries. Perkin was a founding member of SCI and this Medal was first presented to him in New York in 1906.

For more information on the Perkin Medal and the nomination process, visit: soci.org/awards/medals/perkin-medal

Life is busy for Rhys Archer. Outside of her work as EPSRC Doctoral Prize Fellow in Biomedical Materials at the University of Manchester, she founded Women of Science to share stories about real women working in science. She has championed STEM in schools in her spare time and received the Robert Perrin Medal from the Institute of Materials, Minerals, and Mining – all before her 30th birthday.

Rhys is also refreshingly forthright in her views. She took the time to speak to us about everything from attitudes towards disability in academia, the problem with STEM statistics, and finding that sense of belonging in science.

Would you mind telling me about your work at the University of Manchester and the research areas that interest you most?
My research interests have always been interdisciplinary – I am a bit of a magpie when it comes to research and I get excited by projects in different areas. Luckily, being a researcher in materials science means that I can apply my knowledge and skills in a wide array of areas and industries. I have recently finished my doctoral studies looking at how carbon fibre composites are damaged during impacts, and how to toughen them while keeping composites light weight, which is particularly useful in the aerospace industry. However, I have since moved over to research in biomedical materials, specifically within tissue engineering, where I am researching biocompatible composite scaffolds for tissue regeneration.

You set up Women of Science in 2016 to share stories about real people in science. How has this been?
When I set up Women of Science, I first looked at it as a personal project that could be of use in schools to young people. However, it became apparent fairly quickly that access to relatable role-models in STEM was needed, not just in schools but also for women across the STEM industry.

Since then, we have been fortunate to be awarded funding to grow the work we do and expand our audiences. One of the most important actions I have taken with Women of Science is to set up an advisory board (which includes a diverse range of women) to share ideas and to influence the direction and activities of Women of Science.

As well as the impact on others, Women of Science has had a huge impact on me personally. When I set up Women of Science I was going through a difficult period of feeling isolated, and found it difficult to feel a sense of belonging in science and in research. By reaching out and hearing other women’s stories – not just their achievements, but also their doubts, worries, and difficulties – I found that I did belong in STEM. I just had to search for it.

Would you mind sharing some of the successes and challenges you’ve experienced in your own career?
At 29, towards the end of my PhD, I was diagnosed as autistic. Looking back, I can see that the challenges I faced, particularly because of depression, anxiety, and isolation, were due to my needs not being considered or met. Being disabled in academia is an ongoing challenge. It is still a fight to gain equitable working arrangements, opportunities, and acceptance.

However, I can also see how the successes I have had, such as setting up Women of Science, and being a part of other projects are a result of ‘being different’. My strongest quality is a diversity of perspective and experience and an eagerness to be a part of a range of different projects.

>> We’re keen to hear diverse perspectives from people working in the chemical industry. Get in touch with us at: eoin.redahan@soci.org

You have championed inclusivity in STEM. Do you think academic institutions and other workplaces could be more inclusive?
Yes. I think there is a huge amount of awareness and conversation about inclusivity in academia and industry, but not nearly as much action and intervention. Often I see workplaces with inclusive policies, but with little consideration of monitoring, evaluating, or reconsidering those policies. We must move past equity, diversity, and inclusivity being a checkbox exercise. The issues faced by women in the workplace are intersectional and complex, and so require well considered, complex solutions.

According to WISE, women now make up 24% of the STEM workforce in the UK. It estimates that this number could rise to 29% by 2030. What do you think about these figures?
While the number of women in STEM is a common metric when considering equality, this does not accurately portray issues surrounding inclusion and belonging. How are women treated? Do they have the opportunity to advance? Are there equitable policies and measures in place? This is particularly true of women in STEM who identify with other protected characteristics around race, disability, sexual orientation, and class. Once you dig into the statistics (where available) further, it is clear that the numbers given are not sufficient to describe the current situation for all women in STEM.

Also, the ‘leaky pipeline’ model is often considered, that is, that the number of women in STEM fall as we follow the statistics from school, to university, and onto the workplace. However, what is not always considered is that, as with a leaky pipeline, when more women are added, rather than ‘fixing’ the pipeline, the cracks become more obvious. Eventually, we reach a point when the pipeline is fractured. We must focus on repairing these cracks, not just increasing a numerical metric.

Additionally, in this current climate, it is incredibly difficult to make predictions as to what the future holds for the number of women in the STEM workforce. A couple of years ago, we could not foresee the impact that a global pandemic would have on women. When we consider the possible effects of climate change over the next decade, can we predict the burden that will be placed on women, or how this will affect women’s choices?

What’s next for you? Are you involved in any exciting projects?
With Women of Science, we have three projects that will be launched towards the end of the year, including a new website, flashcard activities for young people, and a report on the impact of the pandemic on women in STEM. Further ahead, I would love to expand the reach of Women of Science further, working with podcasting and film, as well as reaching out to policy makers. Personally, I am excited to get my teeth stuck into a new research project and see where that leads, as well as doing more teaching, consulting, and any other opportunities that come my way!

>> Are you interested in getting involved in Women of Science? Visit: www.womenofsci.com

Sarah Davidson has made impressive strides in a short space of time. She has risen to Group Sustainability Coordinator for global Research and Technology at speciality chemicals firm Croda and won the Young Ambassador Award at this year’s Chemical Industry Awards.

In the first blog in our Women in Chemistry series, we caught up with Sarah for a chat on embedding sustainability in the workplace, the need for more diversity in senior roles, and the best bit of advice she received.

Tell us about your career to date.
I loved chemistry at school, so I started off by doing a Master’s in Chemistry at the University of Sheffield. During the course I did a placement year, which was my first taste of working in industry. Once I finished my degree, I was torn between staying in academia and doing a PhD or going into industry. I chose to go into industry because I had enjoyed my placement year so much and saw where I could make an impact.

I was accepted onto Croda’s Graduate Development programme, where I had three placements around the business. Croda is a speciality chemicals company, so my placements included working as an applications scientist and synthetic chemist. However, it was my placement working with the Sustainability team that I loved the most.

After the Grad Scheme I became Group Sustainability Coordinator for Global R&D. This combined my experience in R&D and sustainability in a brand role that didn’t exist in Croda before. This role allows me to use my technical knowledge and understanding of the way the global team works to enable those responsible for Croda’s new product innovations to include sustainability as an integral pillar in new product development.

What does your day-to-day role involve?
In my role, my main focus is on getting our scientists to think about sustainability during product and process development. At a fundamental level this requires me to change their mindsets around sustainability, getting them to see it is important to what we do and understand what it means.

To do this, I have developed a number of tools including checklists, clearly defined procedures and training documents. I have been working to get these new procedures adopted over the global R&D team by fitting them into existing protocols. Another part of my role is to support our corporate targets and I am part of a number of working groups to do this.

One working group looks at how we define a consistent methodology for Life Cycle Assessments or LCA. In this group I have been doing research to understand the current methods around LCA, and what our customers want in terms of sustainability data. I also help gather data to show where we are up to with these goals, so we understand what actions we need to take to move forward. On a day-to-day basis I will have meetings to discuss the projects I am involved in, conduct research and reach out to other teams and functions to see what they are working on too.

Which aspects of your job motivate you most?
For me sustainability is the future, not only for the chemical industry but for the world. Knowing that I am having a positive impact on sustainability in my role is what motivates me the most. I try to live a sustainable life, and what I do at work is just an extension of that.

What personal challenges have you faced and how have you overcome them?
To embed sustainability into our ways of working, I need to change people’s mindsets, and subsequently their behaviour. Seeing this change in people is incredibly rewarding. However, it is also one of the biggest challenges. Some of our teams have been working in the same roles for decades without any change. So, it is my job to make these changes easier for them to adopt and persuade them of the benefits in doing so. To overcome this challenge, I have had to work on my influencing skills and know what will work with the audience I am speaking to.

What is the greatest future challenge for people in your industry and how could this be addressed.
Sustainability, and addressing the issues we face as a result of climate change, are some of the biggest challenges we will face as an industry. We are in a lucky position that we can achieve a competitive advantage with sustainability, but our main goal is to protect our planet. This gives us a big opportunity for collaboration where we may not have had one before. I think we can only solve this challenge by collaborating across the supply chain, across country borders, and between industry and academia.

>> Not everyone takes the standard career path into chemistry. Take a read of Claudio Laurenco’s unusual, inspiring story.

Which mentors have helped you along the way and how did they make a difference?
I feel like I have a long list of mentors and am very lucky to be able to call on so many people for advice. The best thing I have learnt from them is to pursue what I enjoy most, as people will be able to see my passion. This will help me move forward in my career. Having mentors who have confidence in me and my ability has helped me build my own confidence, something which I can lack from time to time. My mentors are great sounding boards for ideas, whether that is to do with things I want to try in my job or on the direction of my career.

What is the current state of play within your sector with respect to equality, diversity, and inclusion – and is enough being done to attract and retain diverse talent?
I don’t think so. We need to do more to attract and retain diverse talent. We seem to be relatively diverse and inclusive at an academic level, which disappears in industry. There must be a reason for this. There may be bias within recruitment processes, or within job descriptions for senior roles, which means there is less diversity as you move up in organisations. We need to make sure that there are equal opportunities within industry for everyone and make sure everyone has a path to progression that works for them.

Is there any advice you would give to young professionals starting out in your area, especially young women?
Understand where you are different and use that as your advantage. Everyone has a unique lived experience that they bring with them into all situations. As women we have a different perspective to men. This doesn’t mean it is less valuable, it is just different. When you feel like you are in a minority as a woman, or are not being listened to, it is important to remember that our opinions are equal regardless of our background, gender or ethnicity. You have the same right to share your views, as the majority do theirs.

>> We’re always keen to hear from women who are making a real difference in chemistry. If you know someone who you think we should cover, please get in touch with us at: eoin.redahan@soci.org.

SCI was pleased to support #BlackInChem, working alongside our Corporate Partners and members to amplify the voices of our Black chemists.

We have heard stories from several Black chemists who highlighted the steps being taken by many companies to increase diversity. But we can also see that there are many more steps that can be taken to encourage the next generation of budding Black chemists and scientists.

#BlackInChem has had support from Scott Bader, an SCI Corporate Partner, with both Damilola Adebayo and Luyanda Mbongwa sharing their perspectives as employees of Scott Bader. Elsewhere, Cláudio Laurenço gave a compelling account of his journey to become a post-doctoral research associate at a leading consumer goods company.

Cláudio Laurenço worked for free and was overlooked before eventually securing his PhD and starting his career in chemistry.

These chemists are following in the footsteps of some pioneering Black scientists such as Percy Lavone Julian, who has been profiled on the SCI Blog.

Many organisations have expressed their support and shared thoughts on what steps they are taking to encourage and ensure diversity. Indeed, #BlackInChem is a global effort and companies such as GSK have shown their support as well as numerous Black chemists talking about their experiences and achievements over the last week.

Percy Lavon Julian’s pioneering work enabled a step-change in the treatment of glaucoma | Editorial credit: spatuletail / Shutterstock.com

Over the coming months, we will be profiling other Black chemists, past and present, and continuing the dialogue around diversity.

>> We’re always keen to hear about diverse perspectives within chemistry. If you’d like to share your story, please contact: muriel.cozier@soci.org or eoin.redahan@soci.org.

For Cláudio Lourenço, the path from student to multidisciplinary scientist has been far from smooth. The Postdoctoral Research Associate reflects on the institutional challenges that almost made him give up, the mentor whose support was so important, and the barriers that block the way for young Black chemists.

Please give a brief outline of your role.
I work for a leading consumer goods company. I am a multi-disciplinary scientist contributing to the development of novel formulations for household products.

Why are you supporting #BlackInChem?
I’m supporting #BlackInChem because I am a champion for diversity. I believe that what we see from our windows in the street is what we must have inside our workplaces. In an ideal world we should all have the same opportunities, but unfortunately this is somehow far from the truth. We need to motivate our young Black chemists to aim for a career in science by providing welcoming environments and real opportunities instead of just ticking boxes. We need to showcase our Black chemists to show to the younger generation that they can also be one of us.

What was it that led you to study chemistry and ultimately develop a career in this field? Was this your first choice?
I have always been passionate about research and science. My father had a pharmacy, so I was always close to chemistry and was a very curious child. Yes, it was my first choice but the lack of opportunities and trust from universities and scholarship providers made it a long run. My motivation faded and I nearly gave up.

Was there any one person or group of people who had a specific impact on your decision to pursue your career path?
Yes, but after my degree I nearly gave up. It took me nearly two years and changing cities to find something (a voluntary position). I was always keen on taking up mentors to show me how to progress in my career. There were a few people who helped me by training me and teaching me how to navigate the scientific world and pursue a career in science.

I only got my first job (which I worked for free) because of Peter Stambrook, an American scholar from the University of Cincinnati, who I met through a friend while polishing glasses in a restaurant. This man was open and keen to put a word in for me at a leading university in the UK. He taught me so much on how to be a scientist and humbly grow up and make a career in science. Eventually, all his advice kept me on the right path.

What impact would you like to see #BlackInChem have over the coming year?
More Black students in postgraduate courses and an increase in role models to motivate the younger generations to pursue careers in chemistry.

Could you outline the route that you took to get to where you are now, and how you were supported?
Personally, my career path was far from easy. I only managed to get my PhD at 38 years of age. I needed to first prove myself. Despite all my efforts and dozens of applications, I was never considered a good candidate. I needed to work for free for two years to land a proper job in my field of choice. During that time I took on many odd jobs to support myself. I worked for a top 10 university for free and they never saw my worth or gave me an opportunity. With that experience I landed a proper job at a leading pharmaceutical company. After one year with them, they funded my PhD studies and now here I am with a career in science.

Considering your own career route, what message do you have for people who would like to follow in your footsteps?
Never ever give up - it is possible. Look for the right mentors and be humble. You do not need to reinvent the wheel, but only to find someone who can lend you theirs. Learn to grow from the experiences of others and be ready to fail a couple of times - we all do. Be open to learn and never be afraid of following your dreams.

>> At SCI, we’re proud to support #BlackinChem. Reach out to us with your stories.

What do you think are the specific barriers that might be preventing young black people from pursuing chemistry/science?
I think one of the biggest barriers that prevent people from pursuing careers in science is the lack of role models. If we only show advertisements for chemistry degrees with White people, it’s not encouraging for Black students to pursue a career there. The same goes for when we visit universities; role models are needed. No one wants to be the only Black person in the department. Universities need to embrace diversity at all levels. I understand that tradition sometimes prevents this, but we need to change and ignore tradition for a bit.

What steps do you think can be taken by academia and businesses to increase the number of Black people studying and pursuing chemistry/science as a career?

Showcase Black chemists and inventors to motivate the younger generations and show society that Black people are not only artists and musicians. Target extracurricular activities in schools where children are from disadvantaged backgrounds. Train your staff to be open. Create cultural events that not only target Black people but also for other people to learn and see that in the end we are all equal. We all need to learn to embrace our differences and grow together.

>> As we celebrate #BlackinChem, we mark the achievements of some inspirational chemists. Read more about the amazing career of Percy Lavon Julian.

This week SCI is joining with business and academia to mark #BlackInChem, an initiative to advance and promote a new generation of Black chemists.

Over the coming weeks, we shall be profiling past and present Black chemists, many of whom are unsung heroes, and whose work established the foundations on which some of our modern science is built. We start with the outstanding contribution made by Percy Lavon Julian (1899-1975).

Born on 11 April 1899 in Montgomery, Alabama, US, Percy L Julian was the son of a clerk at the United State Post Office and a teacher. He did well at school, and even though there were no public high schools for African Americans in Montgomery, he was accepted at DePauw University, Indiana, in 1916.

Due to segregation Julian had to live off campus, even struggling initially to find somewhere that would serve him food. As well as completing his studies, he worked to pay his college expenses. Excelling in his studies, he graduated with a BA in 1920.

Julian wanted to study chemistry, but with little encouragement to continue his education, based on the fact there were few job opportunities, he found a position as a chemistry instructor at Fisk University, Nashville, Tennessee.

In 1922 Julian won an Austin Fellowship to Harvard University and received his MA in 1923. With no job offers forthcoming, he served on the staff of predominantly Black colleges, first at West Virginia State College and in 1928 as head of the department of chemistry at Howard University.

In 1929 Julian received a Rockefeller Foundation grant and the chance to earn his doctorate in chemistry. He studied natural products chemistry with Ernst Späth, an Austrian chemist, at the University of Vienna and received his PhD in 1931. He returned to Howard University, but it is said that internal politics forced him to leave.

Physostigmine was synthesised by Julian

Julian returned to DePauw University as a research fellow during 1933. Collaborating with fellow chemist and friend Josef Pikl, he completed research, in 1935, that resulted in the synthesis of physostigmine. His work was published in the Journal of the American Chemical Society.

Physostigmine, an alkaloid, was only available from its natural source, the Calabar bean, the seed of a leguminous plant native to tropical Africa. Julian’s research and synthesis process made the chemical readily available for the treatment of glaucoma. It is said that this development was the most significant chemical research publication to come from DePauw.

Calabar bean

Once the grant funding had expired, and despite efforts of those who championed his work, the Board of Trustees at DePauw would not allow Julian to be promoted to teaching staff. He left to pursue a distinguished career in industry. It is said that he was denied one particular position as a town law forbid ‘housing of a Negro overnight.’ Other companies are also said to have rejected him because of his race.

However, in 1936 he was offered a position as director of research for soya products at Glidden in Chicago. Over the next 18 years, the results of his soybean protein research produced numerous patents and successful products for Glidden. These included a paper coating and a fire-retardant foam used widely in World War II to extinguish gasoline fires. Julian’s biomedical research made it possible to produce large quantities of synthetic progesterone and hydrocortisone at low cost.

Percy Lavon Julian | Editorial credit: spatuletail / Shutterstock.com

By 1953 Julian Laboratories had been established, an enterprise that he went on to sell for more than $2 million in 1961. He then established the Julian Research Institute, a non-profit research organisation. In 1967 he was appointed to the DePauw University Board of Trustees, and in 1973 he was elected to the National Academy of Sciences, the second African American to receive the honour.

He was also widely recognised as a steadfast advocate of human rights. Julian continued his private research studies and served as a consultant to major pharmaceutical companies until his death on 19 April 1975. Percy Lavon Julian is commemorated at DePauw University with the Percy L Julian Science and Mathematics Center named in his honour. During 1993 the United States Postal Service commemorated Julian on a stamp in recognition of his extraordinary contribution to science and society.

SCI has selected Harriet McNicholl from AstraZeneca as the 2021 National Undergraduate Placement Student of the Year.

The national undergraduate placement symposium brings together chemistry students undertaking industrial research placements each year. Students working in organic, biological, supramolecular, physical organic, medicinal chemistry and related fields are invited to submit posters. The finalists are then selected to present orally at the virtual symposium. This year’s applicants included students from organisations such as AstraZeneca, GlaxoSmithKline, UCB, Syngenta, Charles River and more.

Harriet McNicholl’s chemistry will be used to manufacture drug products to support patients in phase-II clinical trials.

As part of this symposium, Harriet McNicholl from AstraZeneca was invited to present her research to develop a safe, inexpensive and commercially viable process towards AZD5991, a candidate therapeutic for the treatment of acute myeloid leukaemia.

Encapsulating AstraZeneca’s dynamic and data driven approach to turning molecules into medicines, Harriet highlighted how the SELECT criteria, automation and High Throughput Experimentation were used to design and optimise a process. Harriet’s work aimed to maximise efficiency and sustainability, and her chemistry will be used to manufacture drug products to support patients in phase-II clinical trials.

Harriet is in the third year of her chemistry integrated Master’s degree (MChem) at the University of Liverpool and is currently undertaking a synthetic chemistry industrial placement within Chemical Development (CD) at Macclesfield.

‘I have thoroughly enjoyed my placement year within Chemical Development at AstraZeneca,’ she said. ‘It has been incredibly rewarding knowing the science I’ve worked on has the potential to fundamentally transform oncology patients’ lives. This opportunity has enabled me to develop many of my technical and soft skills and motivated me to pursue a career within the pharmaceutical industry.’

Dave Ennis, Vice President of Chemical Development for AstraZeneca in Macclesfield, said: ‘Congratulations to Harriet who has made significant contributions to our development activities in Chemical Development. It is a reflection of the quality of students we attract to our sandwich student programme; I’m proud that we give our students a great insight to drug development by being active participants in our projects, and it is highly motivating for our scientists in helping to coach and develop others - a win-win for all involved.

‘Over the past 25 years, we have had a successful rolling programme of sandwich students from a variety of universities that has helped to attract the next generation of scientific talent to AstraZeneca and the wider industry. Looking forward to our next cohort in 2021, and I’m sure they will compete for the prize next year’.

Harriet’s poster submission

Dr Andrew Carnell, Director of Year in Industry Courses at the Department of Chemistry in the University of Liverpool, added: ‘I am delighted that Harriet has been awarded this prestigious prize for her work during her placement at AstraZeneca. She is a credit to the department and to the university. Our Year in Industry students gain a huge amount from their placements, not only in terms of practical experience and technical knowledge but increased confidence and employability. Students return to us highly motivated for their final year and often go on to secure excellent and rewarding positions in today’s competitive job market.’

As part of this event, keynote speaker James Douglas (Manager of AstraZeneca’s Catalysis, High Throughput and Synthesis Technologies team) noted that his career journey started with a placement year at GlaxoSmithKline in Stevenage. James went on to describe the benefits of doing a placement year and how the skills he gained from his year in industry helped him to secure a Ph.D. at the University of St Andrews and a postdoctoral position with Eli Lilly in the United States.

This year’s competition featured many strong entries. Congratulations to runners up Daniella Hares (AstraZeneca, University of Southampton) for her presentation outlining computational techniques for drug discovery and poster prize winner Jake Odger (Sosei Heptares, University of York). The competition was hosted and organised by the Society of Chemical Industry Young Chemists’ Panel

For more on this year’s National Undergraduate Placement Student of the Year competition, visit: https://istry.co.uk/postercompetition/4/

From genome mining and green synthesis, to tackling tuberculosis and computational methods to help cure malaria, the chemists of tomorrow have been busy showcasing their talents as part of the Society of Chemical Industry Young Chemists Panel’s National Undergraduate Online Poster Competition 2021.

A snapshot of these students’ talents is bottled below in their own words. So, which one of these 15 entries do you think contains the most potential?

1: Genome mining for myxobacterial natural products discovery

Emmanuelle Acs et al., University of Glasgow

Natural products have always had a privileged place in drug development programmes, but their discovery is long and tedious. Genome mining arises as a solution allowing the finding of compounds never seen before. Using an array of bioinformatic softwares, the myxobacterial genome was explored for new Ribosomally and Post-Translationally modified Peptides (RIPPs). Myxobacteria are soil-dwelling bacteria known for the number of secondary metabolites they produce, and they have proven to hide many more within their genome. Indeed, our analyses have led to the potential discovery of nine new myxobacterial natural products. The nature and class of these products is to be confirmed by biosynthesis in the laboratory.

2: De novo design of a lanthanide-binding peptide inspired by the methanol dehydrogenase enzyme active site

Olivia Baldwin et al., University of Birmingham

Lanthanides were thought to be biologically irrelevant until the discovery of bacteria containing the lanthanide-dependent methanol dehydrogenase (Ln-MDH) enzyme. There has been interest in exploiting the attractive properties of the lanthanides by the de novo design of artificial proteins, aiming to explore protein structures and functions not observed in biology. Here, a lanthanide-binding peptide, CS1-0, has been designed de novo and shown to bind to europium and pyrroloquinoline-quinone (PQQ), a key component of the Ln-MDH active site. This partial recreation of a biologically relevant lanthanide binding site is a step towards the ultimate goal of de novo design, to create functional artificial metalloproteins with simplified structures.

3: Template-directed synthesis of porphyrin nanorings: a computational and experimental study

Janko Hergenhahn et al., University of Oxford

Template-directed synthesis provides a route to achieve porphyrin nanorings by favouring ring-closure reaction over oligomerisation. A structurally new template with 12 binding sites has been proposed for the synthesis of novel porphyrin rings; however, initial unsuccessful reactions have raised questions about the binding efficiency of this template to the linear substrate. We have employed classical and quantum modelling together with experimental techniques to explore template-substrate binding in solution and shed light on this process. Titration experiments and modelling have enabled us to study the occupancy of different binding sites and quantify the influence of strain on binding, further guiding novel designs.

4: Transborylation enabled boron-catalysed hydrocyanation of enones

Kieran Benn et al., University of Edinburgh

Hydrocyanation offers an orthogonal route to synthetically ubiquitous amines. Current hydrocyanation methodologies are dominated by the use of acutely toxic hydrogen cyanide gas and transition metal catalysts. Here the application of main-group catalysis and transborylation is reported for the formal hydrocyanation of functionalised alkenes. The catalytic protocol was optimised and applied to a broad range of substrates (20 examples), including examples where chemoselectivity was demonstrated in the presence of reducible functionalities and Lewis basic groups. Mechanistic studies support a proposed catalytic cycle in which B–N/B–H transborylation was a key to catalyst turnover.

Students at the University of Glasgow have used computational analysis to help tackle malaria.

5: Investigation of the structure-property relationship between hydrophobicity and the antimicrobial activity of AMP-mimic copolymers

Xiyue Leng et al., University of Birmingham

Antimicrobial peptides are increasingly employed as new-generation antibiotics, with their amphiphilic nature (contain both hydrophobic and cationic components) mimicked by polymers to enable a more cost-effective approach. However, there is a lack of a quantitative pre-experiment indicator to provide a prospect on their potency. The overall hydrophobicity represented by LogP/SA was proposed to rapidly identify candidates in future designing to reduce synthetic efforts. We show a comparison study between two computational tools used to calculate LogP/SA: ChemBio3D and Materials Studio, in terms of the predictive power and sensitivity, followed by the synthesis of copolymers with a different cationic side chain based on the calculation results.

6: Modelling potential SARS-CoV-2 VIRTAC warheads

Mirjam-Kim Rääbis et al., University of Glasgow

Traditional small molecule therapeutics in medicinal chemistry often require high doses to inhibit the target protein, leading to issues with safety and drug resistance. Proteolysis targeting chimeras (PROTACs) are a new class of molecule that combat these issues, as they can use the body’s own protein degradation systems to degrade targets even at low drug doses. Virus-targeting chimeras (VIRTACs) can use a similar mechanism to target viral proteins. This project uses molecular docking studies to explore potential VIRTAC warheads that target the papain-like protease of SARS-CoV-2, in an attempt to find a potential treatment to COVID-19 that would, among other benefits, offer a lower risk of antiviral resistance.

7: Design, synthesis and biological evaluation of anti-tubercular small molecules

Miriam Turner et al., Newcastle University

Tuberculosis remains one of the top 10 causes of death worldwide, therefore there exists an unmet clinical need for new and improved therapeutics that tackle increasing bacterial resistance and affordability issues. Previous studies indicate N-substituted amino acid hydrazides exhibit good activity against several strains of Mtb. Ongoing structure-activity relationship studies utilising isoniazid, a variety of amino acids, and the active imidazo[1,2-a]pyridine-3-carboxy moiety of clinical candidate Q203 have also demonstrated excellent activities. Herein we report the results of our continued evaluation of this architecture, using a scaffold hopping approach to explore the potential of this pharmacophore as a new anti-tubercular drug.

8: Towards a cure for malaria: computational analysis and design of PfCLK3 inhibitors

Skye Brettell et al., University of Glasgow

Malaria continues to pose a significant challenge to humanity. Resistance to several frontline antimalarials represents a considerable threat, marking the need for new drugs with novel mechanisms of action. Kinase inhibitors represent a potential new class of antimalarials. TCMDC-135051 is a hit compound with activity against malarial kinase PfCLK3 as well as potency in liver, blood and sexual stage parasites. During this project, sequential analysis of the PfCLK3 catalytic domain identified key structural differences between the target and its human orthologs. Molecular docking studies of TCMDC-135051 analogues using GOLD then yielded potential lead compounds with predicted high affinity for the target kinase.

9: Mind the gap! Through-space electronic stabilisation of dynamic azaacene-extended helicene diimides

Matteo Albino et al., University of York

The strain-induced contortion of non-planar, chiroptically-active helicenes caused by fjord steric repulsive interactions is well known. Fjord-mediated planarisation, on the other hand, is far less common and has typically only been achieved via inherently strong covalent bond formation. Herein, I present the properties and density functional theory (DFT) analysis of electroactive aza[5]helicenes exhibiting unexpected through-space π-electronic stabilisation in the reduced states as a result of non-covalent fjord bonding effects. Computational modelling of optical spectra and aromatic-induced current densities reveal that lone pair-repulsive nitrogens in the fjord promote favourable ring currents and reversible helicene planarisation.

10: Mitochondria targeted metal-chelators as potential therapeutic agents against Parkinson’s Disease

Sam Andrew Young et al., Northumbria University

The synthesis of metal chelating molecules, specifically hydroxypyridones (HOPOs), have been identified as potential therapeutic agents for treating Parkinson’s Disease (PD) as bidentate ligands at the two oxygen donor atoms. These ligands are selective for ferric iron in the body, which is expected to stop the reduction of this iron accumulated in the brains of PD sufferers, hindering the Haber-Weiss mechanism from taking place in the mitochondria of the cell and preventing the associated degeneration of the cells. The lipophilicity of these HOPOs is vital to the process, allowing the molecule to transverse the blood-brain barrier, the addition of a triphenylphosphonium group on the HOPO is thought to increase therapeutic effect.

At Heriot Watt University, students have investigated the skin irritation potential of nanoclays using an IATA

11: Green synthesis of n-acetylcolchinol

Adelaide Lunga et al., Loughborough University

The aim of this project is to develop a short synthesis of N-acetylcolchinol using a greener and step-economical pathway. First, aldol condensation of 3-hydroxyacetophenone and 3,4,5-trimethoxybenzaldehye using ethanolic NaOH produced the respective chalcone. The product was reduced electrochemically in DMSO:MeOH (4:1) employing carbon electrodes and NEt4Cl to the saturated benzylic alcohol, which was converted to an acetamide via Ritter reaction using H2SO4 in MeCN. In the final step, the conditions were optimised to enable electrochemical oxidative coupling of the aromatic groups to give the desired N-acetylcolchinol. This novel four-steps reaction sequence avoids use of transition metal catalysts or toxic reagents.

12: Towards the synthesis of small-molecule probes to measure endosulfatase activity

Yi Xiao et al., University of Oxford

Human endosulfatases (SULFs) are enzymes on the cell surface and in the extracellular matrix that hydrolyse 6-O-sulfate on glucosamine units within heparan sulfate proteoglycans. SULFs are involved in growth and development, muscle regeneration and tumour growth via various signaling pathways, with untapped therapeutic and diagnostic potentials. However, profiling SULFs remains a challenge. Antibodies detect their presence, but do not indicate their activity state. The current activity assay is a global sulfatase assay and is not selective in a biological sample. We propose a novel small-molecule probe to profile SULF activity by exploiting the formation of 1,6-anhydrosugar, which can be potentially used in isolated proteins and in vitro.

13: Developing machine learning models to predict the Hansen solubility parameters

Alexander Pine et al., University of Greenwich

Solubility parameters are important for pharmaceutical formulations, paint formulations and new material development. There is a need to improve the accuracy of solubility calculations, and to be able to make rapid predictions of the solubility of new molecular structures. In this project, a range of Python plugins, and open-source codes have been used to develop a Lasso linear regression machine learning model to predict the Hansen solubility parameters (HSP) - δd, δp and δh, which represents dispersion forces, dipole-permanent dipole forces and hydrogen bonding respectively with the intention of making faster and more accurate prediction in solubility.

14: The cycloaddition between cyclononyne and mesyl azide

Alexander David Robertson et al., The University of Glasgow

This research considers computational modelling of a SPAAC reaction involving cyclononyne. DFT calculations were performed on the strain promoted reaction between cyclononyne and mesyl azide. Three low energy conformers of cyclononyne with Cs, C2 and C1 symmetry were found with similar energy. The transition structures for the corresponding cycloaddition with mesyl azide were found and the C2 conformer was the lowest in energy. Product structures were found leading to the identification of the thermodynamic product of the reaction. Distortion/interaction analysis showed that the cycloalkyne was already significantly pre-constrained to its reacting geometry.

15: The assessment of skin irritation potential of nanoclays using an IATA

Holly King et al., Heriot Watt university

Clays are natural nanomaterials consisting of mineral silicate layers. They have several functional uses in everyday life. An example of nanoclays that carry out a wide range of roles is smectites which include montmorillonite (MMT), bentonite and hectorite. These nanoclays can be used in cosmetics, altering their appearance and in pharmaceuticals as drug carriers and wound dressings. Integrated approach to testing and assessment (IATA) aim to collect all relevant data into one easy to understand format that can be used to group materials. Using an IATA dedicated to skin irritation/corrosion it was found that MMT was safe for use. However, hectorite was found to be toxic at high doses indicating that it is a possible irritant to the skin.

Many thanks to the sponsors of this year’s competition: GSK, AstraZeneca, TeledyneIsco. The event runs until 9 July, so let us know what you think of the entries on Twitter at #SCIPosterComp.

If you’d like to see these students’ full posters, go to: https://istry.co.uk/postercompetition/5/?date_example=2021-06-28